Loading...
•
Mar 31
Procter & Gamble Q3 2025 Earnings Report
Procter & Gamble reported stable earnings with modest organic sales growth in Q3 FY2025.
Key Takeaways
P&G delivered steady performance despite a tough environment, with a slight increase in EPS and net income. Organic sales grew modestly, and cash flow remained strong.
Net sales reached $19.8 billion, down 2% from the prior year.
EPS and Core EPS both came in at $1.54, a 1% increase year-over-year.
Organic sales increased by 1%, driven by higher pricing.
Operating cash flow was strong at $3.7 billion, with adjusted free cash flow productivity at 75%.
Procter & Gamble
Procter & Gamble
Procter & Gamble Revenue by Segment
Revenue by Segment
Beauty Revenue
CapyFin.comGrooming Revenue
CapyFin.comHealth Care Revenue
CapyFin.comFabric & Home Care Revenue
CapyFin.comBaby, Feminine & Family Care Revenue
CapyFin.comCorporate Revenue
CapyFin.com Forward Guidance
P&G expects FY2025 sales to be flat with 2% organic growth and a 6-8% increase in diluted EPS.
Positive Outlook
- FY2025 organic sales growth projected at ~2%.
- Core EPS growth expected at 2–4%.
- Diluted EPS forecasted to grow 6–8% vs. FY2024.
- Dividend payments expected to total ~$10B.
- Share repurchases of $6–$7B planned for FY2025.
Challenges Ahead
- $200M after-tax FX headwind anticipated.
- $200M after-tax commodity cost impact expected.
- Net interest income/expense to be a slight headwind.
- Non-repeat of minor brand divestiture benefits from FY2024.
- Potential volatility from geopolitical and macroeconomic pressures.
Revenue & Expenses
Visualization of income flow from segment revenue to net income